Compare Abbott Laboratories (ABT) vs International Business Machines Corp (IBM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs International Business Machines Corp — how do they compare? Abbott Laboratories trades at $95.59 (market cap $166.94B), while International Business Machines Corp trades at $302.98 (market cap $287.73B). The key difference: International Business Machines Corp is the larger of the two by market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | IBM | |
|---|---|---|
Market Cap | $166.94B | $287.73B |
Sector | Health | Technology |
52-Week High | $136.62 | $329.23 |
52-Week Low | $82.57 | $214.64 |
Enterprise Value | $193.69B | $345.75B |
Dividend Yield | 2.63% | 2.21% |
Volume | — | 4,481,527 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
IBM's stock trades at $306.13, up 5.74% today, and is near its consensus price target of $308.14. The technical outlook is bullish with strong moving average signals, though the 6-day RSI indicates overbought conditions. Fundamentally, the company reported revenue of $67.54B in 2025 with a net income margin of 15.61%, and it has beaten earnings estimates for the last three quarters. Recent news highlights product launches in AI and quantum computing.
The outlook is positive with continued earnings momentum and strategic focus on high-growth areas like AI and hybrid cloud. Key risks include competitive pressures in technology and execution challenges in innovation. Analyst sentiment is mixed but leans bullish, with 47% buy ratings. The stock offers a dividend yield supported by strong cash flow from operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About International Business Machines Corp
International Business Machines Corporation (IBM) provides computer solutions. The Company offers application, technology consulting and support, process design and operations, cloud, digital workplace, and network services, as well as business resiliency, strategy, and design solutions. IBM serves clients worldwide.
Read more on IBM →
